-- First oral proteasome inhibitor to be investigated in amyloidosis --
--Trial conducted under Special Protocol Assessment (SPA) from US FDA--
CAMBRIDGE, Mass., October 19, 2012 -- Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating once-weekly oral MLN9708 plus dexamethasone in patients with relapsed or refractory light chain AL amyloidosis. The multi-center study with MLN9708, an investigational oral proteasome inhibitor, plans to enroll patients in Europe, North America, Latin America and the Asia-Pacific region.
"Innovation is essential to the development of investigational therapies, especially in challenging orphan diseases such as amyloidosis," said Karen Ferrante, M.D., Chief Medical Officer, Millennium. "The MLN9708 amyloidosis trial employs a unique study design, including novel endpoints, developed by Millennium in collaboration with the FDA and the hematology community."
"There is a significant unmet medical need in the treatment of light chain amyloidosis, a rare and usually fatal disease," said Professor Giampaolo Merlini, MD, Amyloidosis Research and Treatment Center, University of Pavia, Italy. "There are currently no approved medications for light chain amyloidosis. This innovative study design may allow for earlier identification of clinical benefit for these very sick patients, and may establish a standard for future research in systemic amyloidosis."
Study design
The study known as TOURMALINE-AL1 is a prospective phase 3, randomized, controlled, open-label, multicenter study in patients with relapsed or refractory amyloidosis comparing once-weekly oral MLN9708 plus dexamethasone with investigator selected treatment. Patients in the treatment arm will receive MLN9708 (4.0 mg) orally on Days 1, 8, and 15 plus dexamethasone 20 mg/day weekly on Days 1, 8, 15, and 22 of each 28-day cycle; dexamethasone may be increased up to 40 mg/day after 4 weeks, if tolerated. Patients may continue to receive treatment until progressive disease or unacceptable toxicity, whichever comes first.
Patients in the comparator arm will receive one of the following 28-day treatment options as selected by the physician:
- Dexamethasone or, Dexamethasone plus melphalan or, Dexamethasone plus cyclophosphamide or, Dexamethasone plus thalidomide or, Dexamethasone plus lenalidomide.
The co-primary endpoints are overall hematologic response rate (ORR) including complete response (CR), very good partial response (VGPR), partial response (PR), and rate of 2-year vital organ deterioration and mortality rate. Secondary endpoints include safety, overall survival (OS), complete hematologic response CR, progression free survival (PFS), duration of response (DOR) and quality of life (QOL).
About Amyloidosis
Primary AL amyloidosis occurs when the body's antibody-producing cells do not function properly and produce abnormal protein fibers known as amyloids. These amyloids can form deposits in any organ in the body. The most common organs affected are the kidney, heart, liver, and autonomic or peripheral nerves. The deposits can damage the affected organs and cause them to function less efficiently and may eventually lead to organ failure.
About MLN9708
MLN9708 is an investigational oral, potent, proteasome inhibitor, which is being studied in multiple myeloma, various hematologic malignancies and solid tumors. It is the first oral proteasome inhibitor to enter clinical trials in patients. A global phase 3 trial, TOURMALINE-MM1, to investigate MLN9708 in combination with lenalidomide and dexamethasone in relapsed and/or refractory multiple myeloma has been initiated recently.
Editor's Note: This press release is also available under the Media section of the Company's website at: www.millennium.com/InTheNews.aspx.
About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
About Takeda
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Contacts:
Millennium
David Albaugh
+1-617-444-4456
david.albaugh@mpi.com
Manisha Pai
+1-617-551-7877
Manisha.pai@mpi.com
Takeda Pharmaceutical Company Limited
Corporate Communications Dept. (PR/IR)
Tel: +81-3-3278-2037
Photo: Millennium Thank you card to Patients
YOU ARE LEAVING MILLENNIUM.COM
You are now leaving www.millennium.com. Links to sites outside of Millennium are provided as a resource to the viewer. Millennium accepts no responsibility for the linked sites that Millennium has no control over.
To stay on the current Web site, click "Cancel."
ContinueCancel
Read our social media guidelines below
INTERACTING WITH MILLENNIUM ON SOCIAL MEDIA
Mission
Our mission is to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation, and passion. We recognize the changing communication ecosystem and value our interaction with patients, caregivers, healthcare professionals and anyone else who is interested in learning about our fight against cancer.
As a leading oncology biopharmaceutical organization we hold ourselves to the highest ethical, legal, and regulatory standards unique to this industry. Millennium has established a presence on select channels to engage audiences in a way that meets our objectives of joining in the conversation that social media enables, while responsibly communicating with the public. To do so, we have developed a set of guidelines to better help our followers understand the unique parameters of how we will utilize these platforms.
Definition of Social Media
For our purposes, social media are online services where users can interact with one another. Millennium chooses to participate in some, but not all, of these services. Current channels in which Millennium participates:
Other services may be added. Check back occasionally to see all of the channels we support.
Comments and Other User-Generated Content
Many of the channels in which we participate allow for comments and other additions by members of the public. Examples of topics that we encourage include posts you approve of, ways we can improve our posts, and suggestions for other topics you would like to see.
Comments on our social media properties are welcome; however, we are required by law to moderate all comments to ensure we stay within government regulations. Comments are moderated for adherence to our terms and conditions posted on each channel, which state:
In scenarios when Millennium cannot post or must remove your comment, we will attempt to send a private message to you explaining why. Otherwise, have at it. Millennium wants to hear from you about our work in the fight against cancer.
References to Millennium from Your Own Property
Often social media channels will allow you to link to or reference a Millennium social media account. We welcome this interaction, however, we will not respond to inflammatory posts, hateful attacks on Millennium or other social media channel users, or obscene language. The topic restrictions listed above apply to posts that mention us, and we cannot reply to any that violate our terms and conditions. Unlike comments on our own properties, we will not attempt to contact someone who mentions us in violation of the above.
We will do our best to answer your comments and questions; however, there may be some things we cannot address, such as questions directly related to financial, legal, regulatory, confidential information, or medical issues.
DISCLAIMER
Millennium does not endorse any user or associated products and services of any social media user that interacts with our profiles. Millennium may link to an external website for interest or convenience. Millennium claims no responsibility for the content of sites over which we have no control, and are not liable for any damages or injury arising from that content. Millennium reserves all rights relating to our social media profiles and properties, including discontinuing the Page, removing unwanted connections, responding to any questions or comments, and removing or modifying any content posted to the profile.